EE9900587A - CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul - Google Patents

CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul

Info

Publication number
EE9900587A
EE9900587A EEP199900587A EEP9900587A EE9900587A EE 9900587 A EE9900587 A EE 9900587A EE P199900587 A EEP199900587 A EE P199900587A EE P9900587 A EEP9900587 A EE P9900587A EE 9900587 A EE9900587 A EE 9900587A
Authority
EE
Estonia
Prior art keywords
blockade
protein inhibitor
therapeutic protein
exogenous protein
inhibitor syndrome
Prior art date
Application number
EEP199900587A
Other languages
English (en)
Estonian (et)
Inventor
Adelman Burt
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9900587A publication Critical patent/EE9900587A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
EEP199900587A 1997-06-20 1998-06-19 CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul EE9900587A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (fr) 1997-06-20 1998-06-19 Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques

Publications (1)

Publication Number Publication Date
EE9900587A true EE9900587A (et) 2000-08-15

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900587A EE9900587A (et) 1997-06-20 1998-06-19 CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul

Country Status (25)

Country Link
US (1) US20020119151A1 (fr)
EP (1) EP1034001B1 (fr)
JP (1) JP2002504910A (fr)
KR (1) KR100567998B1 (fr)
CN (2) CN1261285A (fr)
AT (1) ATE272408T1 (fr)
AU (1) AU733062B2 (fr)
BG (1) BG64436B1 (fr)
BR (1) BR9810755A (fr)
CA (1) CA2294138A1 (fr)
CZ (1) CZ295805B6 (fr)
DE (1) DE69825473T2 (fr)
EA (1) EA002512B1 (fr)
EE (1) EE9900587A (fr)
ES (1) ES2226152T3 (fr)
HK (1) HK1031825A1 (fr)
HU (1) HUP0002048A3 (fr)
IL (1) IL133305A0 (fr)
IS (1) IS2097B (fr)
NO (1) NO996274L (fr)
NZ (1) NZ502051A (fr)
PT (1) PT1034001E (fr)
SK (1) SK285962B6 (fr)
TR (1) TR199903141T2 (fr)
WO (1) WO1998058672A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142069A0 (en) * 1998-09-21 2002-03-10 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2001079555A2 (fr) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles des membres de la famille jak/stat dans l'induction de la tolerance
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030306A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EP2248830A1 (fr) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps antagonistes anti-CD40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantés
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法

Also Published As

Publication number Publication date
EP1034001B1 (fr) 2004-08-04
KR100567998B1 (ko) 2006-04-07
HK1031825A1 (en) 2001-06-29
HUP0002048A2 (hu) 2000-10-28
DE69825473T2 (de) 2005-08-04
PT1034001E (pt) 2004-12-31
SK285962B6 (sk) 2007-12-06
CA2294138A1 (fr) 1998-12-30
US20020119151A1 (en) 2002-08-29
NZ502051A (en) 2001-04-27
HUP0002048A3 (en) 2002-09-30
AU8153698A (en) 1999-01-04
ATE272408T1 (de) 2004-08-15
TR199903141T2 (xx) 2000-09-21
EA002512B1 (ru) 2002-06-27
KR20010013964A (ko) 2001-02-26
NO996274D0 (no) 1999-12-17
BG104092A (en) 2000-10-31
EA200000059A1 (ru) 2000-08-28
BG64436B1 (en) 2005-02-28
CZ458899A3 (cs) 2000-04-12
ES2226152T3 (es) 2005-03-16
NO996274L (no) 2000-02-18
JP2002504910A (ja) 2002-02-12
EP1034001A1 (fr) 2000-09-13
DE69825473D1 (de) 2004-09-09
WO1998058672A1 (fr) 1998-12-30
CZ295805B6 (cs) 2005-11-16
IL133305A0 (en) 2001-04-30
IS2097B (is) 2006-04-12
CN1651071A (zh) 2005-08-10
CN1261285A (zh) 2000-07-26
SK180399A3 (en) 2000-06-12
IS5274A (is) 1999-11-26
AU733062B2 (en) 2001-05-03
BR9810755A (pt) 2000-08-15

Similar Documents

Publication Publication Date Title
EE9900587A (et) CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
DK0782445T3 (da) Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
NO20016007L (no) Rekombinant anti-CD40-antistoff og anvendelser derav
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
SE9800836D0 (sv) New Compounds
EP1181585A4 (fr) Regulateur, isolateur, melangeur et diviseur de faisceaux de polarisation a large bande
WO2001024816A3 (fr) Compositions et procedes d'inhibition de la caseomorphine et de la gluteomorphine
HK1038882A1 (zh) 通過共同給予血管生成抑制劑增強抗體-細胞因子融合蛋白介導的免疫應答
IS5247A (is) Notkun CD40:CD154 bindingarrofa til að koma í vegfyrir ónæmissvörun gegn aðlögun, einkum höfnun græðlinga
DK641589A (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
NO923089D0 (no) Tetrahydroindazol, tetrahydrocyklopentapyrazol og heksahydrocykloheptapyrazol forbindelser og deres anvendelse som hmg-coa reduktase-hemmere
DK0936902T3 (da) Spraytørrede mikropartikler som terapeutiske bærere til anvendelse i terapi
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
EP1185283A4 (fr) Nouvelle utilisation therapeuthique de la proteine modulatrice de l'inflammation virale pour bloquer le rejet d'une xenogreffe
WO2003099212A3 (fr) Compositions d'inhibiteurs d une proteine kinase activee par des agents mitogenes et utiles dans la therapie du lymphome
PL314799A1 (en) Application of dimeticone in treating constipations
AU9294698A (en) Methods and compositions for enhanced wound healing
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
NO20001846D0 (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
BR9612245A (pt) Inibidor de óxido nitrico (no) sintase para tratamento ou prevenção de diabetes tipo ii
WO2004017902A3 (fr) Ubiquitine et molecules liees a l'ubiquitine destinees au traitement et a la prevention d'une activation nuisible du systeme immunitaire

Legal Events

Date Code Title Description
HC1A Change of owner name